Mark Fishman

Mark C.
Fishman is Lead Independent Director at Beam Therapeutics, Inc. since 2018.
Director at Aditum Bio Fund 1 LP since 2019.
Non-Executive Director at Versanis Bio, Inc. Director at Teres Bio, Inc. Director at Anteris Bio, Inc. Chief-Pathways Clinical Service at The General Hospital Corp.
Trustee-Emeritus at The Children's Hospital of Philadelphia.
Former Chairman of Novartis Institute for Functional Genomics, Inc. Chairman of Semma Therapeutics, Inc. from 2016 to 2019.
Director at Novartis International Pharmaceutical Ltd. Founding Director of Cardiovascular Research Center.
Director at Geneception, Inc. Member-Executive Board at Novartis AG.
Founding President of Novartis Institutes for Biomedical Research, Inc. from 2002 to 2016.
Trustee at The Marine Biological Laboratory.
Professor at Harvard Medical School.
Education includes undergraduate degree from Yale University in 1972 and doctorate from Harvard Medical School in 1976.